𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside

✍ Scribed by H. D. Preisler; J. Epstein; M. Barcos; R. Priore; A. Raza; G. P. Browman; R. Vogler; E. Winton; H. Grunwald; K. Rai; J. Brennan; J. Bennett; J. Goldberg; A. Gottlieb; P. Chervenick; R. Joyce; K. Miller; R. Larson; P. D'Arrigo; T. Doeblin; M. Stein; M. Bloom; R. Steele; H. Lee

Book ID
114710302
Publisher
John Wiley and Sons
Year
1984
Tongue
English
Weight
781 KB
Volume
58
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose cytosine arabinoside: Clinical
High-dose cytosine arabinoside: Clinical response to therapy in acute leukemia
✍ Early, A. P. ;Preisler, H. D. ;Higby, D. J. ;Brecher, M. ;Browman, G. ;McBride, 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 664 KB

High dose cytosine arabinoside (HD-AraC) was evaluated 1) as remission induction therapy for refractory acute leukemia and high risk AML, 2) as augmentation therapy for acute leukemia, and 3) as conditioning therapy prior to allogeneic bone marrow transplantation for acute leukemia. Seven of 10 pati

Treatment of acute nonlymphocytic leukem
Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside
✍ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours